Medivation, Inc. clinical trials
Acquired by Pfizer, Sep 28, 2016 · source ↗
The registry lists 14 studies whose lead sponsor is Medivation, Inc.. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Nov 25, 2016.
- 14studies on the registry
- 0open to participants now
Before and after it joined Pfizer
- First submitted before Medivation, Inc. became part of Pfizer
- 14
- First submitted after Medivation, Inc. became part of Pfizer
- 0
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
What it is testing
The drugs Medivation, Inc.’s studies test, most studies first; none is open now — 2 drugs with a page of their own. Each count opens the studies in search.
Studies, none open
- latrepirdine6 in phase 30 open · 11
- 0 open · 3
All 14 at a glance
Where each study is in its life, its phase and its countries. Each count opens them in search.
Over the years
- 07
- 08
- 409
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 026
By the year each study started; 2 started before 2007. 2026 so far in the lighter column.
Registry sponsor names on this page
- Medivation, Inc.14 studies
Something wrong with this grouping? Tell us on the Pfizer page.
Studies
Recruiting first, then most recently updated. Showing 14 of 14. All Pfizer studies →
- Efficacy and Safety Study of MDV9300 in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)WithdrawnNCT02653989Phase 2
Sponsor listed in the registry: Medivation, Inc. · First submitted before Medivation, Inc. became part of Pfizer
- An Extension of the HORIZON Protocol Evaluating the Safety of Dimebon (Latrepirdine) in Subjects With Huntington DiseaseTerminatedNCT01085266Phase 3
Sponsor listed in the registry: Medivation, Inc. · First submitted before Medivation, Inc. became part of Pfizer
- A Safety and Efficacy Study of Dimebon in Patients With Huntington DiseaseCompletedNCT00920946Phase 3
Sponsor listed in the registry: Medivation, Inc. · First submitted before Medivation, Inc. became part of Pfizer
- Safety and Efficacy Study Evaluating Dimebon in Patients With Mild to Moderate Alzheimer's Disease on DonepezilCompletedNCT00829374Phase 3
Sponsor listed in the registry: Medivation, Inc. · First submitted before Medivation, Inc. became part of Pfizer
- An Extension of the CONCERT Protocol (DIM18)TerminatedNCT01152216Phase 3
Sponsor listed in the registry: Medivation, Inc. · First submitted before Medivation, Inc. became part of Pfizer
- A Safety and Efficacy Study of Oral Dimebon in Patients With Mild-To-Moderate Alzheimer's DiseaseCompletedNCT00675623Phase 3
Sponsor listed in the registry: Medivation, Inc. · First submitted before Medivation, Inc. became part of Pfizer
- A Safety and Efficacy Study Evaluating Dimebon (Latrepirdine) in Patients With Moderate to Severe Alzheimer's DiseaseTerminatedNCT00954590Phase 3
Sponsor listed in the registry: Medivation, Inc. · First submitted before Medivation, Inc. became part of Pfizer
- Safety, Tolerability and Efficacy Study of the Monoclonal Antibody, CT-011, in Patients With Metastatic MelanomaCompletedNCT01435369Phase 2
Sponsor listed in the registry: Medivation, Inc. · First submitted before Medivation, Inc. became part of Pfizer
- Study of Combination Therapy With Dimebon and Donepezil (Aricept) in Patients With Alzheimer's DiseaseTerminatedNCT00704782Phase 2
Sponsor listed in the registry: Medivation, Inc. · First submitted before Medivation, Inc. became part of Pfizer
- Double-blind, Placebo-controlled Study of Oral Dimebon in Subjects With Mild to Moderate Alzheimer's DiseaseCompletedNCT00377715Phase 2
Sponsor listed in the registry: Medivation, Inc. · First submitted before Medivation, Inc. became part of Pfizer
- Safety and Tolerability of Dimebon in Patients on Memantine, and Memantine Plus DonepezilCompletedNCT00829816Phase 1
Sponsor listed in the registry: Medivation, Inc. · First submitted before Medivation, Inc. became part of Pfizer
- Study to Evaluate the Safety, Tolerability and Efficacy of FOLFOX + CT-011 Versus FOLFOX AloneCompletedNCT00890305Phase 2
Sponsor listed in the registry: Medivation, Inc. · First submitted before Medivation, Inc. became part of Pfizer
- A Study of the Novel Drug Dimebon in Patients With Huntington's DiseaseCompletedNCT00497159Phase 2
Sponsor listed in the registry: Medivation, Inc. · First submitted before Medivation, Inc. became part of Pfizer
- Safety Study of the Novel Drug Dimebon to Treat Patients With Huntington's DiseaseCompletedNCT00387270Phase 1/2
Sponsor listed in the registry: Medivation, Inc. · First submitted before Medivation, Inc. became part of Pfizer